DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Aktueller Standort:
>
> This Story


Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Japanese startup to develop ultra-compact proton therapy system Designed to replace conventional radiotherapy systems

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Varian to acquire Cancer Treatment Services International for $283 million Enables production of multidisciplinary solutions

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

New 12-year study highlights value of PRRT, based on long-term outcomes Understanding peptide receptor radionuclide therapy

RefleXion Medical secures $60 million for approval and launch of BgRT system Can detect and treat multiple tumors in the same session

Korean cancer center aims to deploy heavy ion therapy in 2022 Plans also call for the onboarding of more CR and MR systems

Radiation oncologists appeal to Congress to safeguard radiotherapy treatment Protecting cancer patients' access to value-based care

Using ERISA to end proton therapy denials Insights from Timothy J. Rozelle and Lisa S. Kantor, from Kantor & Kantor, LLP on getting insurers to provide coverage

Philips unveils IntelliSpace Radiation Oncology system at ESTRO Manages complexity and efficiency of radiology departments

Precision-based medicine improves outcomes and drives down costs

From the June 2017 issue of DOTmed HealthCare Business News magazine

Insurers may be more apt to approve precision medicine techniques when considering a cost-benefit analysis. For cancer patients, expenses will drop as they receive targeted medication within days of diagnosis, and are able to skip more toxic treatments that result in hospitalization, intravenous lines, complications of those, steroids and other medication to lessen side effects and nursing. For example, a report by PricewaterhouseCoopers indicates that a genetic test on breast cancer patients could save an estimated $1,900 per patient because it can reduce chemotherapy use between 20 and 35 percent. Likewise, increased diagnostic accuracy for cancer screenings will reduce the costs and morbidity associated with false positive tests.

In hospitals, where insurance reimbursement rates depend upon patient experience and satisfaction, and expenditures are always closely monitored, precision medicine is already improving outcomes. In one study, precision medicine was shown to reduce readmissions by 52 percent, reduce visits to the emergency department by 42 percent and decrease deaths by 85 percent. Hospitals have a responsibility to their patients (and shareholders) to proactively promote new advancements in medicine. They should utilize their considerable clout to support research and development companies during FDA trials to ensure their physicians have access to the latest precision therapies once approved.
Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.




With the passage of the 21st Century Cures Act, precision medicine has received the backing of the U.S. government. The bill, which provides $4.8 billion in funding to initiatives aimed at matching patients to treatments based on their genes, signals a shift toward creating new health care standards. With the ability to fund more genetic sequencing, it is my hope that we can develop new treatment and diagnostic approaches for a wide range of cancers.

About the author:
Paul Crowe is chairman and CEO of Nuview Life Sciences. Crowe is an experienced health care executive who, over the past 40 years, participated in the commercialization of new diagnostic imaging technologies such as diagnostic ultrasound, magnetic resonance imaging and positron emission tomography (PET). These technologies provided physicians with better tools to more effectively diagnose, and subsequently treat, chronic human diseases, improved patient outcomes and lowered health care costs.

Back to HCB News
<< Pages: 1 - 2

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Werben
Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Übersicht
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Gesundheitsdienstleister
Alle Gesundheitsdienstleister-Tools anzeigen
Jobs/Training
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED